SLC5A2 and diabetic kidney disease: Tofogliflozin, a highly specific inhibitor of SGLT2, exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by curbing the formation of AGEs and oxidative stress in the kidney [17].